Research Paper Volume 3, Issue 5 pp 533—542
Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans
- 1 Division of Geriatrics and Nutritional Sciences, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA;
- 2 Department of Nutritional and Dietetics, St. Louis University, St. Louis, MO 63104, USA;
- 3 Geriatrics, University of New Mexico School of Medicine and New Mexico VA Health Care System, NM 87108, USA;
- 4 Division of Nutrition and Aging, Instituto Superiore di Sanità Rome Italy 00161
Received: April 8, 2011 Accepted: May 9, 2011 Published: May 10, 2011https://doi.org/10.18632/aging.100327
How to Cite
Plasma dehydroepiandrosterone (DHEA) decreases ~80% between ages 25 and 75 yr. In a preliminary study, we found that 6 mo of DHEA replacement improved insulin action in elderly individuals. The purpose of the present larger, randomized double-blind study was to determine whether a longer period of DHEA replacement improves glucose tolerance. Fifty-seven men and 68 women aged 65 to 75 yr were randomly assigned to 50 mg DHEA or placebo once daily. Year one was a randomized, double blind trial. Year 2 was an open label continuation. DHEA replacement improved glucose tolerance in participants who had abnormal GT initially, reduced plasma triglycerides, and the inflammatory cytokines IL6 and TNFα.
This trial was registered at clinicaltrials.gov as NCT00182975.
Dehydroepiandrosterone (DHEA) and its sulfated form (DHEAS), which will be referred to together as DHEA, are secreted by the zona reticularis of the adrenal cortex only in humans and related primate species . DHEA is present in far higher concentrations in plasma than any other steroid hormone . Adrenal production of DHEA begins during puberty, peaks at ~20 yr and begins to decline with aging beginning at ~25 yr [2,3]. This decline is progressive and severe, resulting in a plasma DHEA level by age 75 yr that is ~80% lower than at 20 yr . It has been reported that DHEA level predicts longevity in men . Studies on laboratory rodents have shown that DHEA treatment reduces total and visceral fat accumulation and protects against development of muscle insulin resistance in response to a high fat diet [5,6], with advancing age , and in genetic obesity [8,9].
In a preliminary study to test the hypothesis that, as in rodents, DHEA replacement reduces adiposity and improves insulin action, we evaluated the effects of six months of DHEA treatment (50 mg/day) in a randomized controlled trial on 56 elderly women and men . The DHEA treatment induced significant decreases in abdominal fat and in the insulin area under the oral glucose tolerance curve, without a change in glucose levels, providing evidence for an increase in insulin sensitivity. The present study was undertaken to determine whether a longer period of DHEA replacement improves both insulin action and glucose tolerance in elderly women and men.
Of the 659 people who initially expressed interest in the study, 335 did not meet the inclusion criteria and 188 chose not to participate (Figure 1). The remaining 136 eligible volunteers were randomized to one year of DHEA replacement, 50 mg daily, or placebo. After completing the 12 mo randomized study, 112 of the participants volunteered to continue in an open-label study for an additional 12 mo. In the open-label study, the participants who had been randomized to DHEA replacement continued taking DHEA for a second year, while those who had been in the placebo group crossed over to DHEA replacement for 12-mo.
There were no significant differences between the DHEA and placebo groups in gender distribution, age or body mass index (BMI) (Table 1). More of the participants in the placebo group were on anti-dyslipidemic medications (Table 1). Seventy-one percent of the participants in the DHEA group had abnormal oral glucose tolerance tests (2 hr glucose value above 140 mg/dl) initially compared to 52% of those in the placebo group (Table 1).
Table 1. Characteristics of the Participants
|DHEA||Placebo||Between Group P value|
|Abbreviations: DHEA, dehydroepiandrosterone; BMI, body mass index|
|Age, yr||70 ± 3||70 ± 3||0.84|
|BMI, kg/m2||28.4 ± 5.6||27.6 ± 4.9||0.40|
Normal glucose tolerance
Abnormal glucose tolerance
|History of cardiovascular disease||8||8||0.97|
Based on pill count, the percentage of prescribed doses taken averaged 94 ± 0.4% in the DHEA and 96 ± 0.4% in the placebo group.
Physical Activity and Energy Intake
Energy intake, estimated from food records, averaged 2191 ± 62 kcal/day before and 2181 ± 67 kcal/day after 12 mo of DHEA replacement, and 2116 ± 56 kcal/day before and 2151 ± 68 kcal/day after 12 mo in the placebo group.
Body Weight and Composition
The men in the DHEA group had a small but significant decrease in body weight during the first year of DHEA replacement, while the men in the placebo group gained weight (Table 2). The DHEA replacement resulted in small but significant decreases in body fat percentage and total fat mass in the male participants, while the men in the placebo group had small but significant increases (Table 2). Trunk and appendicular fat masses showed a similar reduction (Table 2). Abdominal visceral fat, evaluated using MRI, underwent a very small, but statistically significant, decrease in the men in the DHEA group; however, the difference between the changes in visceral fat between the DHEA and placebo groups was not significant (Table 2). There were no significant changes in body weight in the women in either the DHEA or placebo group. The only significant change in body composition in the women was a small increase in fat free mass in the DHEA group.
Table 2. Body Weight and Body Composition Before and After 12 months of DHEA
|Group||Baseline||12 Mos||Between-group||Baseline||12 Mos||Between-group|
|Body weight, kg||DHEA Placebo||88.2±2.5 83.8±2.2||87.3±2.6* 84.5±2.2||-1.6±0.6||0.008||72.5±2.9 75.1±3.0||72.9±2.9 75.0±3.0||0.5±0.7||0.47|
|Body fat percentage||DHEA Placebo||28.0±1.0 25.3±1.2||27.2±1.1* 25.9±1.2*||-1.3±0.4||0.001||39.1±1.1 40.0±1.1||38.7±1.1 40.3±1.2||-0.7±0.4||0.09|
|Fat mass, kg||DHEA Placebo||25.2±1.5 21.7±1.5||24.4±1.6* 22.4±1.5*||-1.6±0.5||0.001||29.1±1.9 30.9±2.0||29.0±1.9 31.1±2.0||-0.3±0.5||0.53|
|Fat-free mass, kg||DHEA Placebo||63.0±1.2 62.1±1.2||62.9±1.2 62.1±1.1||-0.1±0.3||0.81||43.3±1.1 44.2±1.2||43.9±1.2* 43.9±1.2||0.8±0.3||0.01|
|Trunk fat mass, kg||DHEA Placebo||14.5±1.0 11.9±0.9||14.1±1.0 12.3±0.9*||-0.9±0.3||0.009||14.1±0.9 14.7±0.9||14.0±0.9 14.8±1.0||-0.2±0.3||0.51|
|Appendicular fat mass, kg||DHEA Placebo||9.7±0.6 8.8±0.6||9.2±0.6* 9.0±0.6||-0.7±0.2||0.0001||14.2±1.0 15.3±1.1||14.1±1.0 15.4±1.1||-0.2±0.3||0.52|
|VAT, cm3||DHEA Placebo||2151±167 1720±218||2065±168* 1765±214||-117±62||0.06||932±106 906±92||909±108 895±90||-11±44||0.81|
|SAT, cm3||DHEA Placebo||2021±139 1694±102||1970±134 1773±97||-96±61||0.12||2177±187 2282±149||2194±191 2305±144||-9±61||0.88|
|p≤0.05 versus baseline within group and gender. Visceral and subcutaneous adipose tissue volumes exclude data from 12 participants who did not undergo MRI scans due to metal prostheses or implants. VAT, abdominal visceral adipose tissue volume; SAT, abdominal subcutaneous adipose tissue volume.|
During the second year of DHEA replacement, body weight, total fat mass and trunk and appendicular fat masses did not change significantly in the men (data not shown). The men who crossed-over from placebo to DHEA had no significant changes in body weight or body fat during the 12 mo of DHEA replacement. The only change in body composition in the women who crossed over from placebo to 12 mo of DHEA was a 0.5 ± 0.2 kg (P<0.01) increase in fat free mass.
Oral Glucose Tolerance Test
One year of DHEA replacement resulted in significant decreases in the glucose values at the 60 min, 90 min and 120 min time points of the oral glucose tolerance test (OGTT) and in the glucose area under the curve (AUC) (Figure 2C). A similar effect of DHEA replacement was seen in the participants in the placebo group who crossed over to DHEA in the second year open label study (data not shown). Insulin levels during the OGTT tended to be lower after one year of DHEA replacement, but the decrease did not attain statistical significance (p=0.06 for change in area under the insulin curve) (Figure 2D). However, the product of the glucose AUC and insulin AUC, an indicator of insulin resistance , was significantly improved, i.e. reduced, in response to one year of DHEA replacement (~22%, p,0.01), and was unchanged in the placebo group.
Figure 2. Oral glucose tolerance test results from the 1-yr randomized placebo-controlled trial. Changes in the areas under the curve for glucose and insulin did not differ significantly between the placebo group (panels A and B) and the DHEA group (panels C and D) (glucose, p=0.09; insulin, p=0.52). *p<0.05 for baseline to 1-yr change within group. AUC, area under the curve.
It was evident on evaluation of the data, that improvements in glucose tolerance in response to DHEA occurred only in those participants who had abnormal glucose tolerance. We, therefore, did a separate analysis on the glucose tolerance data of the participants who had abnormal glucose tolerance initially. The improvements in glucose tolerance and AUC after one year (Figure 3C) of DHEA replacement was considerably greater when the results are not diluted by the values obtained on the participants with normal glucose tolerance. There were no significant changes in insulin levels during the OGTT except for the 120 min value, which was lower after 12 mo of DHEA (Figure 3D). The improvements in glucose tolerance persisted during the additional 12 mo of open label DHEA replacement (Figure 3E). There was no improvement in glucose tolerance in the participants with normal glucose tolerance.
Figure 3. Oral glucose tolerance test results for subjects with abnormal glucose tolerance at baseline. The reduction in the glucose area under the curve (AUC) in the DHEA group (panel C) was significantly greater than that for the placebo group (panel A, p=0.03). Changes in insulin area under the curve did not differ between groups (panels B and D, p=0.52). Improvements in the glucose area under the curve were maintained in a subset of DHEA group participants who underwent a second year of DHEA supplementation (panel E). *p<0.05 for baseline versus DHEA.
The hormone data on most of the participants in this study have been reported previously in a paper describing the effects of the DHEA replacement on bone mineral density . In both men and women, the DHEA replacement increased plasma DHEAS into the young normal range (men 68±7 to 371±23μg/dl; women 41±5 to 293±21 μg/dl). In the men, DHEA replacement resulted in small, but statistically significant increases in testosterone, estradiol and their free indexes (~12%, p<0.05). In the women, testosterone and estradiol levels, and their free indexes increased about 2-fold in response to DHEA replacement.
DHEA replacement resulted in a significant decrease in plasma triglycerides (DHEA: 120±10 mg/dl to 105±8 mg/dl; Placebo: 103±8 mg/dl to 110±8 mg/dl; p<0.05 within DHEA group; p<0.05 between groups). There were no significant effects of DHEA on total, LDL, or HDL cholesterol in the men. DHEA replacement resulted in a 9% decrease in HDL cholesterol in women (p<0.01). This decrease had reversed by the end of the second year of DHEA replacement (initial 58±2, 12 mo 53±2, 24 mo 56 ± 2 mg/dl, means ± SE).
There were significant decreases in the plasma concentrations of TNFα and IL-6 in response to 1 year of DHEA replacement (Table 3).
Table 3. Circulating Inflammatory Cytokines
|DHEA Group||Placebo Group||Adjusted Difference Between Groups||Between Group P value|
|Abbreviations: TNFα, tumor necrosis factor α; IL-6 interleukine-6|
|TNF-α, pg/mL Baseline 12 months Change Within group P value||1.43 ± 0.13 1.25 ± 0.09 -0.18 ± 0.09 0.18||1.34 ± 0.16 1.62 ± 0.22 0.27 ± 0.16 0.04||-0.43±0.18||0.02|
|IL-6, pg/mL Baseline 12 months Change Within group P value||2.73 ± 0.20 2.32 ± 0.15 -0.41 ± 0.13 0.004||2.45 ± 0.16 2.93 ± 0.17 0.48 ± 0.15 0.0008||-0.78±0.17||<0.0001|
There were 12 serious adverse events and 124 minor events, with no difference in frequency between groups.
There were no serious adverse events attributable to DHEA replacement. Mild adverse events were development of acne in two women, which cleared up spontaneously, and increased facial hair growth in another woman. PSA levels averaged 1.10 ± 0.13 mg/ml at baseline and 1.07 ± 0.12 mg/dl after 12 mo in the men on DHEA, and 0.95 ± 0.13 mg/dl at baseline and 0.98 ± 0.12 mg/dl after 12 mo in the men in the placebo group. Based on mammograms and pap smears, no evidence of breast cancer or cervical abnormalities were detected in the women. Serum markers of liver function were unaffected by DHEA replacement.
In our previous study, 6 mo of DHEA replacement resulted in an improvement in insulin action evidenced by a smaller increase in insulin during an OGTT without a change in glucose response . In the present study, a longer period of DHEA replacement resulted not only in a reduction in insulin resistance, but also in improved glucose tolerance, in elderly, overweight or obese women and men with abnormal glucose tolerance. The magnitude of this improvement was impressive, as DHEA replacement for 1 yr resulted in an 18 mg/dl decrease in the 2h glucose value of the OGTT (p,0.02 vs. placebo) and 2 yr of DHEA resulted in a 21 mg/dl in the 2h glucose value. These findings have relevance to the current epidemic of impaired glucose tolerance and type 2 diabetes  because they raise the possibility that DHEA could be an effective treatment for impaired glucose tolerance and for prevention of type 2 diabetes.
Visceral fat, measured by MRI, decreased ~10% in both men and women . This finding, together with the observation that DHEA protects laboratory rodents against visceral fat accumulation and insulin resistance with aging  and in response to high fat diets [5,6], led us to conclude that DHEA improves insulin action largely by reducing intra-abdominal fat .
While the present results confirm that DHEA replacement decreases insulin resistance in individuals with abnormal glucose tolerance, they do not support our previous conclusion that this improvement is largely mediated by a decrease in visceral fat. In the present study, the women had a small increase in fat free mass without a decrease in abdominal fat, while the men had only a small decrease in visceral fat in response to DHEA, suggesting that the reduction in visceral fat observed in our previous, 6 mo study is a transient effect.
In addition to our earlier study , other studies have found an improvement in insulin action in response to DHEA replacement, including in hypoadrenal women , middle-aged hypercholesterolemic men , and postmenopausal women . However, in contrast to the present results, it was recently reported by Nair et al.  and Basu et al.  that two years of DHEA treatment had no effect on insulin action or postprandial glucose turnover in elderly men and women. The difference between the results of their study and ours, despite a similar study design, would be puzzling were it not for our finding that DHEA replacement improved glucose tolerance/insulin resistance only in those participants who had abnormal glucose tolerance, with no improvement in those with normal glucose tolerance. Although Nair et al.  and Basu, et al.  did not perform a standard OGTT, it appears that their subjects were unusually insulin sensitive for their age. This is evidenced by a fasting insulin level of ~3.6 μU/ml, a value similar to that of their young controls and about 50% lower than that of our participants with abnormal glucose tolerance, a fasting glucose value ~5 mgdl lower than that of our participants, and a calculated HOMA index  of insulin resistance of 0.88 compared to 1.88 for our participants with abnormal glucose tolerance. Thus, the lack of effect of DHEA on insulin action in the study by Nair et al.  and Basu et al.  is in keeping with our finding that DHEA improves insulin action only in individuals with abnormal glucose tolerance.
Regarding mechanisms by which DHEA may reverse insulin resistance, one possibility is by activation of PPARα for which DHEA is a ligand [19,20]. Activated PPARα stimulates expression of the mitochondrial enzymes involved in fat oxidation and represses activation of enzymes involved in fat synthesis[20,21]. As a result, PPARα activation lowers triglycerides , and could result in less fat deposition in liver and muscle. PPARα activation also suppresses inflamemation , and DHEA has been shown to inhibit nuclear factor Kappa B and production of IL-6 and TNFα by various cell types, and to lower circulating levels of these inflammatory cytokines [22-26]. Chronic inflammation in adipose tissue and macrophages is thought to be one of the factors that mediates insulin resistance [27,28]. In the present study, DHEA replacement resulted in significant reductions in plasma IL-6 and TNFα, suggesting a decrease in inflammation. It is of interest relative to a role of PPARα activation in the improvement in insulin action induced by DHEA, that fibrates, which mediate their effects on lipid metabolism by activating PPARα , have also been reported to improve insulin action and glucose tolerance [29-36].
Another mechanism by which DHEA or some of its metabolites might enhance insulin action is by improving impaired activation of phosphatidyl inositol 3-kinase and Akt/PkB by insulin in insulin resistant muscle [37-39]. It is interesting in this regard that 17α-ethynyl-5-androstene-3β, 7β, 17β triol, an analog of a DHEA metabolite, enhances insulin-stimulated Akt/PkB phosphorylation in muscle, and improves muscle and liver insulin sensitivity and glucose tolerance in Zucker diabetic rats and improves insulin sensitivity in insulin resistant humans .
In conclusion, the results of this study confirm our previous finding that DHEA replacement in elderly men and women improves insulin action . They further show that a longer period of DHEA treatment than was evaluated in our previous study, 12 mo vs. 6 mo, also significantly improves glucose tolerance, and that this improvement occurs only in those individuals who have abnormal glucose tolerance. These findings raise the possibility that DHEA could become a first line treatment for glucose intolerance/insulin resistance and diabetes prevention in older individuals and ameliorate the increase in chronic inflammation that occurs with aging.
Men and women, aged 65-75y were recruited from the Saint Louis area. Screening included a medical history, physical examination, blood chemistry analysis, hematology, urinalysis, and electrocardiography. Volunteers were excluded if they were current smokers or if they had evidence of chronic infection, a history or evidence of malignancy within the past 5 yr, clinical cardiovascular disease, advanced emphysema, advanced Parkinson's disease, resting blood pressure >170 mmHg systolic or >100 mmHg diastolic, or diabetes (self-report or fasting plasma glucose ≥ 126 mg/dL). Participants taking medications were required to maintain stable dosing regimens for six months prior to the study. Informed written consent was obtained from the participants, and the study was approved by the Human Research Protection Office at Washington University School of Medicine.
Participants were randomized to 12 months of 50 mg/d DHEA or placebo. Both groups received multivitamin and calcium/vitamin D supplements and were advised to maintain their usual diet and physical activity. During monthly meetings with the study nurse, participants received a month's supply of DHEA or placebo, had pill counts performed, and were questioned about adverse events, changes in activity level, diet, and medications.
Oral Glucose Tolerance Test (OGTT)
OGTTs (75g) were started in the morning after an overnight fast. The study dietitian instructed the participants to consume ≥ 250 g/day carbohydrate for the three days preceding the test. Plasma glucose and insulin were measured using the glucose oxidase method (model 2300 Stat Plus, YSI Inc., Yellow Springs, Ohio) and radioimmunoassay . Incremental area under the curve (AUC) was calculated for OGTT glucose and insulin values by the trapezoidal method . Because of technical problems year 2 insulin data were not available. Although volunteers with self-reported diabetes or a fasting plasma glucose ≥126 mg/dL were excluded from the study, results from the baseline OGTT indicated that 16 of the enrolled participants had diabetes based on a 2-hr glucose ≥200 mg/dL. These participants were not excluded.
Fasting Blood Analyses
Plasma total cholesterol, HDL-cholesterol, and glycerol-blanked triglycerides (TGs) were measured by a CLIA-certified clinical laboratory using automated enzymatic/colorimetric assays (Roche/Hitachi Modular Analytics System; Roche Diagnostics Corporation, Indianapolis, IN). Tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6) (Quantikine High Sensitive, R&D Systems, Minneapolis, MN) were measured by using ELISA.
Body Composition, Body Mass, and Height
Whole body fat mass and fat free mass, Truncal fat and appendicular fat mass, were measured by dual X-ray absorptiometry (DXA) (Delphi W, software version 11.2; Hologic Corporation, Waltham MA). Visceral and subcutaneous abdominal adipose tissue volumes were measured using magnetic resonance imaging. Ten serial 10-mm axial images were acquired using a 1.5-T super-conducting magnet (Siemens, Iselin, NJ), beginning at the first lumbar vertebra and moving downward. Images were batch analyzed with HIPPO software (version 1.3, Pisa, Italy) [42,43]. Slice level fat volumes were summed to get total adipose tissue volumes for the region of interest.
Physical activity levels were assessed using the Aerobic Center Longitudinal Study Physical Activity Questionnaire . The questionnaire is designed to assess habitual physical activity performed over the past 3 months.
We are grateful to Mrs. Victoria Reckamp for expert assistance in preparation of this manuscript. This study was supported by National Institutes of Health research grants AG020076, NIH General Clinical Research Center Grant RR00036, NIH grant P30DK056341 and NIH grant number UL1RR024992. EPW was supported by NIH National Research Service Award AG00078 and DK080886.
Conflicts of Interest
The authors of this paper declare no conflict of interests.
- 1. Hornsby PJ. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann N Y Acad Sci. 1995; 774:29-46. [PubMed]
- 2. Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydro-epiandrosterone sulfate in normal men. J Clin Endocrinol Metab. 1992; 75:1002-1004. [PubMed]
- 3. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984; 59:551-555. [PubMed]
- 4. Enomoto M, Adachi H, Fukami A, Furuki K, Satoh A, Otsuka M, Kimagae S, Nanjo Y, Shigetoh Y, Imaizumi T. Serum dehydroepiandrosterone sulfate levels predict longevity in men: 27-year follow-up study in a community-based cohort (Tanushimaru study). J Am Geriatr Soc. 2008; 56:994-998. [PubMed]
- 5. Mohan PF, Ihnen JS, Levin BE, Cleary MP. Effects of dehydroepiandrosterone treatment in rats with diet-induced obesity. J Nutr. 1990; 120:1103-1114. [PubMed]
- 6. Hansen PA, Han D-H, Nolte LA, Chen M, Holloszy JO. DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high fat diet. Am J Physiol:Regulatory. 1997; 273:R1704-R1708..
- 7. Han D-H, Hansen PA, Chen MM, Holloszy JO. DHEA treatment reduces fat accumulation and protects against insulin resistance in male rats. J Gerontol Biol Sci. 1998; 53:B19-B24..
- 8. Cleary MP, Zabel T, Sartin JL. Effects of short-term dehydroepiandrosterone treatment on serum and pancreatic insulin in Zucker rats. J Nutr. 1988; 118:382-387. [PubMed]
- 9. Kimura M, Tanaka S, Yamada Y, Kiuchi Y, Yamakawa T, Sekihara H. Dehydroepiandrosterone decreases serum tumor necrosis factor-a and restores insulin sensitivity: independent effect from secondary weight reduction in genetically obese Zucker fatty rats. Endo. 1998; 139:3249-3253..
- 10. Villareal DT and Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. JAMA. 2004; 292:2243-2248. [PubMed]
- 11. Matsuda M and DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. DiabetesCare. 1999; 22:1462-1470..
- 12. Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr. 2009; 89:1459-1467. [PubMed]
- 13. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005; 54:765-769. [PubMed]
- 14. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, Miyamoto S, Nakano M, Ogawa H. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003; 88:3190-3195. [PubMed]
- 15. Lasco A, Frisina N, Morabito N, Gaudio A, Morini E, Trifiletti A, Basile G, Nicita-Mauro V, Cucinotta D. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol. 2001; 145:457-461. [PubMed]
- 16. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Man CD, Tindall DJ, Melton LJ, Smith GE, Khosla S, Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. N Eng J Med. 2006; 355:1647-1659..
- 17. Basu R, Man CD, Campioni M, Basu A, Nair KS, Jensen MD, Khosla S, Klee G, Toffolo G, Cobelli C, Rizza RA. Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women. Diabetes. 2007; 56:753-766. [PubMed]
- 18. Matthews DR, Hosker JP, Rodenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412-419. [PubMed]
- 19. Peters JM, Zhou Y-C, Ram PA, Lee SST, Gonzalez FJ, Waxman DJ. Peroxisome proliferator-activated receptor a required for gene induction by dehydroepiandrosterone-3b-sulfate. Mol Pharmacol. 1996; 50:67-74. [PubMed]
- 20. Poynter ME and Daynes RA. Peroxisome proliferator-activated receptor a activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1998; 273:32833-32841. [PubMed]
- 21. LeFebvre P, Chinetti G, Fruchart J-C, Staels B. Sorting out the roles of PPARa in energy metabolism and vascular homeostasis. J Clin Invest. 2006; 116:571-580. [PubMed]
- 22. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Schölmerich J, Falk W, Lang B. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. 83:1998; 2017.
- 23. Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M, Nakashima N. Dehydroepiandrosterone-sulfate inhibits nuclear factor-kB-dependent transcription in hepatocytes, possibly through antioxidant effect. J Clin Endocrinol Metab. 2004; 89:3449-3454. [PubMed]
- 24. Altman R, Motton DD, Kota RS, Rutledge JC. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARa and NF-kB. Vascul Pharmacol. 2008; 48:76-84. [PubMed]
- 25. Gutiérrez G, Mendoza C, Zapata E, Montiel A, Reyes E, Montaño LF, López-Marure R. Dehydroepiandrosterone inhibits the TNFa-induced inflammatory response in human unbilical vein endothelial cells. Atherosclerosis. 2007; 190:90-99. [PubMed]
- 26. Kipper-Galperin M, Galilly R, Danenberg HD, Brenner T. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor a and interleukin-6 in astrocytes. Int J Dev Neurosci. 1999; 17:765-775. [PubMed]
- 27. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007; 132:2169-2180. [PubMed]
- 28. Fève B and Bastard JP. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2009; 5:305-311. [PubMed]
- 29. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg H, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004; 109:2197-2202. [PubMed]
- 30. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, Baba S. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. DC. 1988; 11:495-499..
- 31. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wójcik J, Zarnecki A, Blane G. Effects of comicronised fenofibrate on lipids and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest. 2000; 30:871-878. [PubMed]
- 32. Mussoni L, Mannucci L, Sirtori C, Pazzucconi F, Bonfardeci G, Cimminiello C, Notarbartolo A, Scafidi V, Bittolo Bon G, Alessandrini P, Nenci G, Parise P, Colombo L, Piliego T, Tremoli E. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis. 2000; 148:397-406. [PubMed]
- 33. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab. 2006; 91:1770-1778. [PubMed]
- 34. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor a activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000; 275:16638-16642. [PubMed]
- 35. Furuhashi M, Ura N, Murakami H, Hyakukoku M, Yamaguchi K, Higashiura K, Shimamoto K. Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol. 2002; 174:321-329. [PubMed]
- 36. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes. 2001; 50:411-417. [PubMed]
- 37. Lu M, Patsouris D, Li P, Flores-Riveros J, Frincke JM, Watkins S, Schenk S, Olefsky JM. A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats. Am J Physiol:Endocrin Metab. 2010; 298:E1036-E1048..
- 38. Campbell CS, Caperuto LC, Hirata AE, Araujo EP, Velloso LA, Saad MJ, Carvalho CR. The phosphatidylinositol/AKT/atypical PKC pathway is involved in the improved insulin sensitivity by DHEA in muscle and liver of rats in vivo. Life Sci. 2004; 76:57-70. [PubMed]
- 39. Sato K, Iemitsu M, Aizawa K, Ajisaka R. DHEA improves impaired activation of Akt and PKC zeta/lambda-GLUT4 pathway in skeletal muscle and improves hyperglycaemia in streptozotocin-induced diabetes rats. Acta Physiol (Oxf). 2009; 197:217-225. [PubMed]
- 40. Morgan DR and Lazarow A. Immunoassay of insulin: two antibody system. Diabetes. 1963; 12:115-126..
- 41. Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer FX. The use of areas under curves in diabetes research. DiabetesCare. 1995; 18:245-250..
- 42. Arif H, Racette SB, Villareal DT, Holloszy JO, Weiss EP. Comparison of methods for assessing abdominal adipose tissue from magnetic resonance images. Obesity. 2007; 15:2240-2244. [PubMed]
- 43. Positano V, Gastaldelli A, Sironi AM, Santarelli MF, Lombardi M, Landini L. An accurate and robust method for unsupervised assessment of abdominal fat by MRI. J Magn Reson Imaging. 2004; 20:684-689. [PubMed]
- 44. The Aerobics Center Longitudinal Study Physical Activity Questionnaire. Med Sci Sports Exerc. 1997; 6:(Suppl) 10-14..